Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update

Context Therapeutics Inc. (NASDAQ:CNTX) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,530,000 shares, an increase of 55.1% from the December 15th total of 986,300 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average daily volume of 501,500 shares, the short-interest ratio is currently 3.1 days.

Context Therapeutics Stock Up 3.2 %

Shares of NASDAQ CNTX traded up $0.03 on Friday, hitting $1.01. The company had a trading volume of 259,944 shares, compared to its average volume of 366,240. Context Therapeutics has a 12-month low of $0.89 and a 12-month high of $2.75. The firm has a market capitalization of $75.75 million, a P/E ratio of -1.11 and a beta of 2.10. The business has a 50 day moving average of $1.36 and a two-hundred day moving average of $1.89.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, sell-side analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on CNTX shares. JMP Securities initiated coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Wednesday. Finally, Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $6.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Driehaus Capital Management LLC acquired a new position in Context Therapeutics in the 2nd quarter worth $4,527,000. Great Point Partners LLC purchased a new stake in shares of Context Therapeutics during the second quarter worth about $14,876,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the second quarter worth about $10,348,000. State Street Corp grew its stake in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in Context Therapeutics during the 2nd quarter valued at approximately $3,881,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.